Skip to main content
Addgene

pcDNA3.1-TK1
(Plasmid #100544)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 100544 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pCDNA3.1+
  • Backbone manufacturer
    invitrogen
  • Backbone size w/o insert (bp) 5428
  • Vector type
    Mammalian Expression
  • Selectable markers
    Neomycin (select with G418)

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    thymidine kinase 1
  • Alt name
    TK2
  • Alt name
    TK1
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    705
  • Entrez Gene
    TK1 (a.k.a. TK2)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site EcoRV (not destroyed)
  • 3′ cloning site XhoI (not destroyed)
  • 5′ sequencing primer CMV-F
  • 3′ sequencing primer BGH-rev
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pcDNA3.1-TK1 was a gift from Yuh-Shan Jou (Addgene plasmid # 100544 ; http://n2t.net/addgene:100544 ; RRID:Addgene_100544)
  • For your References section:

    Pyrimidine metabolic rate limiting enzymes in poorly-differentiated hepatocellular carcinoma are signature genes of cancer stemness and associated with poor prognosis. Yeh HW, Lee SS, Chang CY, Hu CM, Jou YS. Oncotarget. 2017 Sep 8;8(44):77734-77751. doi: 10.18632/oncotarget.20774. eCollection 2017 Sep 29. 10.18632/oncotarget.20774 PubMed 29100421